Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

References

• YangQYinCLiaoFBevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancerOnco Targets Ther201582407241326366095
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• CostaTNuñezJFelisminoTBoenteLMelloCREOX: evaluation of the efficacy of retreatment with an oxaliplatin-containing regimen in metastatic colorectal cancer: a retrospective single-center studyClin Colorectal Cancer201716431632328392022
   PubMed Web of Science ®Google Scholar
• AbramsTAMeyerGSchragDMeyerhardtJAMoloneyJFuchsCSChemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancerJ Natl Cancer Inst20141062djt37124511107
   PubMedGoogle Scholar
• SaravananSPariLProtective effect of thymol on high fat diet induced diabetic nephropathy in C57BL/6J miceChem Biol Interact201624511126680107
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working GroupBiomarkers and surrogate endpoints: preferred definitions and conceptual frameworkClin Pharmacol Ther2001693899511240971
   PubMed Web of Science ®Google Scholar
• CremoliniCAntoniottiCPietrantonioFSurrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysisCancer Res Treat201649383484527857020
   PubMed Web of Science ®Google Scholar
• ShiQde GramontAGrotheyAZalcbergJChibaudelBSchmollHJIndividual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system databaseJ Clin Oncol2015331222825385741
   PubMed Web of Science ®Google Scholar
• CartwrightTHYimYMYuEChungHHalmMForsythMSurvival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncologyClin Colorectal Cancer201211423824622658457
   PubMed Web of Science ®Google Scholar
• OhharaYFukudaNTakeuchiSRole of targeted therapy in metastatic colorectal cancerWorld J Gastrointest Oncol2016159642655
   Web of Science ®Google Scholar
• BurzykowskiTBuyseMPiccart-GebhartMJEvaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerJ Clin Oncol200826121987199218421050
   PubMed Web of Science ®Google Scholar
• SaadEDKatzAHoffPMBuyseMProgression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literatureAnn Oncol201021171219901012
   PubMed Web of Science ®Google Scholar
• BikovKAMullinsCDHungASealBOnukwughaEHannaNPatterns of biologics use across treatment lines in elderly (age >65) Medicare patients with metastatic colon cancerOncologist201621667668327125751
   PubMed Web of Science ®Google Scholar
• HeinemannVvon WeikersthalLFDeckerTFOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialLancet Oncol201415101065107525088940
   PubMed Web of Science ®Google Scholar
• PrasadVKimCBurottoMVandrossAThe strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analysesJAMA Intern Med201517581389139826098871
   PubMed Web of Science ®Google Scholar
• CianiODavisSTappendenPValidation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makersInt J Technol Assess Health Care201430331232425308694
   PubMed Web of Science ®Google Scholar
• MichielsSSaadEDBuyseMProgression-free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumorsDrug2017777713719
   PubMed Web of Science ®Google Scholar
• BurzykowskiTBuyseMPiccart-GebhartMJEvaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerJ Clin Oncol2017261219871992
   Web of Science ®Google Scholar
• HellmannMDChaftJEWilliamWNJrUniversity of Texas MD Anderson Lung Cancer Collaborative GroupPathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpointLancet Oncol20141514250
   PubMed Web of Science ®Google Scholar
• HanKRenMWickWProgression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trialsNeuro Oncol201416569670624335699
   PubMed Web of Science ®Google Scholar
• HalabiSRiniBEscudierBStadlerWMSmallEJProgression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinomaCancer20141201526024347384
   PubMed Web of Science ®Google Scholar
• RosePGTianCBookmanMAAssessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group studyGynecol Oncol2010117232432920185168
   PubMed Web of Science ®Google Scholar
• BuyseMBurzykowskiTCarrollKProgression-free survival is a surrogate for survival in advanced colorectal cancerJ Clin Oncol200725335218522418024867
   PubMed Web of Science ®Google Scholar
• GiessenCLaubenderRPAnkerstDPSurrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trialsActa Oncol201554218719325017379
   PubMed Web of Science ®Google Scholar
• PetrelliFPietrantonioFCremoliniCEarly tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysisEur J Cancer201551780080725794604
   PubMed Web of Science ®Google Scholar